BridgeMD
Does GLP-1 medication improve the effects of vaccination in people with diabetes?
EU CTIS ID: 2026-525909-13-00
What this study is testing
The primary objective of this study is to assess whether initiaion of a GLP-1 receptor agonist improves the immunological response to a pneumococcal vaccine.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- T2DM without GLP-1: have a diagnosis of T2DM and a clinical indication to start with a GLP-1RA due to non-optimal HbA1c or very-high cardiovascular risk.
- Healthy controls: have a BMI between 18 and 25 kg/m2, have no active chronic disease, and do not use medication (except for birth control pills or occasional painkiller).
- T2DM with GLP-1: have a diagnosis of T2DM and use a stable dose of semaglutide for ≥1 year. Matching will occur on BMI, glycaemic control and cardiovascular risk profile.
You likely can't join if
- Had a previous pneumococcal vaccination in the last five years or any vaccination in the last four weeks
- An infection in the prior four weeks
- Current pregnancy/breastfeeding
- End-stage renal disease
- Use of anti-inflammatory therapy
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.